Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2020-05-07 Major Shareholding Noti…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a decrease due to market sales) by a major shareholder (S-MAC Co., Ltd.) in a listed company (Lumi Micro Co., Ltd.). This type of filing is used to notify the market of significant changes in shareholding thresholds, which corresponds to the 'Major Shareholding Notification' category.
2020-05-07 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the terms, recipients, and legal basis for the stock option grant. Since this is a specific regulatory disclosure regarding corporate capital/equity structure changes (stock options) and does not fit into the other specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), it is best classified as a general Regulatory Filing (RNS).
2020-05-07 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). It details the terms of the bond, including interest rates, conversion prices, put/call options, and the use of proceeds. This falls under capital structure changes and financing activities, which is classified as 'Capital/Financing Update'.
2020-05-06 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange. It details the decision to issue convertible bonds (전환사채권 발행결정), including terms like interest rates, conversion prices, put/call options, and the use of proceeds. This falls under the category of capital structure changes and financing activities, which is classified as 'CAP' (Capital/Financing Update).
2020-05-06 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is a 'Major Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). It details the terms of the bond, interest rates, conversion rights, and call/put options. This type of regulatory filing for capital structure changes, specifically debt financing, falls under the 'Capital/Financing Update' category.
2020-05-06 Korean
[기재정정]타법인주식및출자증권처분결정
M&A Activity Classification · 95% confidence The document is a regulatory filing from a Korean company (Lumi Micro) regarding the amendment of a previously announced disposal of shares in another corporation (Kumho HT). It details the change in the expected disposal date and provides updated financial terms. Since this is a specific regulatory disclosure regarding a corporate transaction (disposal of assets/shares) that does not fit into the other specific categories like M&A (which usually implies full takeovers) or Share Issue, it is classified as a general Regulatory Filing (RNS).
2020-04-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.